Hansa Medical AB Stock Price, News & Analysis

HNSBF OTC Link

Company Description

Hansa Biopharma AB is a pioneer in immunoglobulin G (IgG)-cleaving enzyme technology, developing innovative treatments for rare immunological conditions. With conditional marketing approval in Europe, their unique antibody-cleaving enzyme, imlifidase, targets IgG and inhibits IgG-mediated immune response. The recent 16-HMedIdeS-12 phase 2 trial demonstrated that imlifidase significantly reduced donor-specific antibodies (DSAs) in patients with antibody-mediated rejection (AMR) episodes following a kidney transplant. The trial showcased a 94.4% reduction in DSAs compared to standard of care, highlighting the potential of imlifidase in improving patient outcomes. In addition to kidney transplants, Hansa Biopharma is exploring the use of imlifidase in autoimmune diseases such as anti-glomerular basement membrane (anti-GBM) disease, Guillain-Barré Syndrome, and ANCA-associated vasculitis.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$259.2M

Market Cap

82.7M

Shares outstanding

Latest News

View All

28 days ago

0.00%

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

clinical trial

January 7, 2025

0.00%

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

conferences

May 21, 2024

0.00%

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

conferences

December 14, 2023

0.00%

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

clinical trial

April 20, 2023

0.00%

Hansa Biopharma interim report January-March 2023

September 12, 2022

0.00%

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

SEC Filings

View All

No SEC filings available for Hansa Medical AB.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Loading short interest data...

Days to Cover History

Last 12 Months

Loading days to cover data...

Frequently Asked Questions

What is the current stock price of Hansa Medical AB (HNSBF)?

The current stock price of Hansa Medical AB (HNSBF) is $4.58 as of October 1, 2025.

What is the market cap of Hansa Medical AB (HNSBF)?

The market cap of Hansa Medical AB (HNSBF) is approximately 259.2M. Learn more about what market capitalization means .

What is Hansa Biopharma AB known for?

Hansa Biopharma AB is known for pioneering immunoglobulin G (IgG)-cleaving enzyme technology and developing innovative treatments for rare immunological conditions.

What is imlifidase, and how does it work?

Imlifidase is a unique antibody-cleaving enzyme that originates from Streptococcus pyogenes. It specifically targets IgG and inhibits IgG-mediated immune response by cleaving IgG-antibodies and inhibiting their activity within hours after administration.

What recent trial results did Hansa Biopharma AB announce?

Hansa Biopharma AB announced full results from the 16-HMedIdeS-12 phase 2 trial, showing a significant reduction in donor-specific antibodies (DSAs) within the first five days of treatment with imlifidase in patients with antibody-mediated rejection (AMR) episodes following a kidney transplant.

In which patient populations is imlifidase being explored for potential benefits?

In addition to kidney transplant patients, Hansa Biopharma AB is studying the use of imlifidase in autoimmune diseases such as anti-glomerular basement membrane (anti-GBM) disease, Guillain-Barré Syndrome, and ANCA-associated vasculitis.

What sets imlifidase apart from other treatments?

Imlifidase's rapid onset of action, ability to cleave IgG-antibodies, and inhibit their activity quickly after administration differentiate it from other treatments in reducing donor-specific antibodies and addressing IgG-mediated immune responses.